Donanemab

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

Potential clinical meaningfulness of donanemab data

Topline donanemab results: most positive Phase III data to date

Prospects for Alzheimer’s disease monitoring and treatment in 2023

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Use of AD blood-based biomarkers for trial enrolment

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Future direction for anti-amyloid immunotherapies

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Is amyloid lowering still a valid approach in Alzheimer’s disease?

Important developments in dementia: biomarkers & clinical trials

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?